A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
Keytruda LoE: A seismic shift for oncology?
Immune checkpoint inhibitors (ICIs) have changed the face of oncology treatment since their initial entry in the early 2010s. Driven mostly by the group of...